Document is current

Article History

Received: 13 February 2018

Accepted: 20 April 2018

First Online: 9 May 2018

Ethics approval and consent to participate

: Existing deidentified specimens and associated clinical data was submitted to OmniSeq from Roswell Park Comprehensive Cancer Center (Buffalo, NY), Fox Chase Cancer Center (Philadelphia, PA), Dartmouth-Hitchcock Medical Center (Lebanon, NH), Northwest Oncology (Munster, IN), Hospital Universitario Virgen Macarena (Sevilla, Spain), Columbia University (New York, NY), and Miami Cancer Institute (Miami, FL) with institutional review board approval from each individual institution. OmniSeq’s analysis utilized deidentified data that was considered non-human subjects research under IRB-approved protocol (BDR #073166) at Roswell Park Comprehensive Cancer Center (Buffalo, NY).

: Disclosures: MZ, PG, KD, KS, KGM, LJT, NS, DK, LDLCM, IA, YS, MB, MVC, and ZD have no conflicts of interest to disclose. SP, JMC, MKN, STG, DD, APS, BB, JA, VG, MQ, YW, FLL, MG, and CM are all employees of OmniSeq, Inc. (Buffalo, NY) and hold restricted stock in OmniSeq, Inc. AO, WB, IP, CM, STG, JMC, and MSE are employees of Roswell Park Comprehensive Cancer Center (Buffalo, NY). Roswell Park Comprehensive Cancer Center is the majority shareholder of OmniSeq, Inc. MSE, RD, and LG provide remunerated consulting to OmniSeq, Inc. ME and SMA are employees of Laboratory Corporation of America Holdings (Burlington, NC). Laboratory Corporation of America Holdings, (Burlington, NC) is a shareholder in OmniSeq, Inc.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.